학술논문
'학술논문'
에서 검색결과 69건 | 목록
1~10
Academic Journal
Banez MT; Department of Pharmaceutical Services, University of California, San Francisco, California, USA.; Atienza S; Department of Pharmacy, Advocate Health Midwest, Milwaukee, Wisconsin, USA.; Butts A; Department of Pharmacy, UK HealthCare, Lexington, Kentucky, USA.; Derba M; Department of Pharmacy, Eastern Maine Medical Center, Bangor, Maine, USA.; Dicke K; Department of Pharmacy, OhioHealth, Columbus, Ohio, USA.; Haverstick K; Pharmacy and Therapeutics Service Line, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.; Heron BB; National Pharmacy Benefits Management, Hematology/Oncology, Department of Veterans Affairs, Hines, Illinois, USA.; Cimino SK; Department of Pharmaceutical Services, Vanderbilt University Medical Center, Nashville, Tennessee, USA.; Loop MS; Department of Health Outcomes Research and Policy, Harrison College of Pharmacy, Auburn University, Auburn, Alabama, USA.; Hough S; The US Oncology Network, McKesson Specialty Health, The Woodlands, Texas, USA.; Merten JA; Chimeric Medical Communications, LLC, St Ansgar, Iowa, USA.; Moore DC; Department of Pharmacy, Atrium Health Levine Cancer Institute, Charlotte, North Carolina, USA.; Shah V; Department of Pharmacy, Mayo Clinic, Phoenix, Arizona, USA.; Taucher KD; Department of Pharmacy, UCHealth, Aurora, Colorado, USA.; Zhang JM; Department of Pharmacy, University of Chicago Medical Center, Chicago, Illinois, USA.; Mahmoudjafari Z; University of Kansas Health System, Kansas City, Kansas, USA.
Publisher: SAGE Publications Country of Publication: England NLM ID: 9511372 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-092X (Electronic) Linking ISSN: 10781552 NLM ISO Abbreviation: J Oncol Pharm Pract Subsets: MEDLINE
Academic Journal
Shahzad M; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA.; H. Lee Moffitt Cancer Center, Tampa, Florida, USA.; Mikael Rayaan Foundation Global Health Consortium, Kansas City, USA.; Amin MK; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA.; Mikael Rayaan Foundation Global Health Consortium, Kansas City, USA.; Bellman P; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA.; Al-Ramahi J; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA.; Mikael Rayaan Foundation Global Health Consortium, Kansas City, USA.; Noor J; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA.; Vyas A; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA.; Mahmoudjafari Z; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA.; Mikael Rayaan Foundation Global Health Consortium, Kansas City, USA.; McGuirk M; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA.; DeJarnette S; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA.; Mikael Rayaan Foundation Global Health Consortium, Kansas City, USA.; Ahmed N; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA.; Mikael Rayaan Foundation Global Health Consortium, Kansas City, USA.; Abdallah AO; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA.; Mikael Rayaan Foundation Global Health Consortium, Kansas City, USA.; Shune L; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA.; Mikael Rayaan Foundation Global Health Consortium, Kansas City, USA.; Singh AK; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA.; Mikael Rayaan Foundation Global Health Consortium, Kansas City, USA.; McGuirk JP; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA.; Mikael Rayaan Foundation Global Health Consortium, Kansas City, USA.; Abhyankar S; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA.; Mikael Rayaan Foundation Global Health Consortium, Kansas City, USA.; Mushtaq MU; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA.; Mikael Rayaan Foundation Global Health Consortium, Kansas City, USA.
Publisher: American Association Of Blood Banks Country of Publication: United States NLM ID: 0417360 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1537-2995 (Electronic) Linking ISSN: 00411132 NLM ISO Abbreviation: Transfusion Subsets: MEDLINE
Academic Journal
In: JACCP Journal of the American College of Clinical Pharmacy . (JACCP Journal of the American College of Clinical Pharmacy, July 2024, 7(7):621-630)
Academic Journal
Dima D; Department of Hematology/Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA. dimad@ccf.org.; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS, USA. dimad@ccf.org.; Abdallah AO; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS, USA.; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS, USA.; Davis JA; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS, USA.; Division of Hematology/Oncology, Medical University of South Carolina, Charleston, SC, USA.; Awada H; Department of Hematology/Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA.; Goel U; Department of Hematology/Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA.; Rashid A; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS, USA.; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS, USA.; DeJarnette S; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS, USA.; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS, USA.; Anwer F; Department of Hematology/Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA.; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS, USA.; Shune L; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS, USA.; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS, USA.; Raza S; Department of Hematology/Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA.; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS, USA.; Mahmoudjafari Z; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS, USA.; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS, USA.; Williams L; Department of Hematology/Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA.; Faiman B; Department of Hematology/Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA.; McGuirk JP; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS, USA.; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS, USA.; Sauter CS; Department of Hematology/Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA.; Ahmed N; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS, USA.; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS, USA.; Khouri J; Department of Hematology/Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA.; Hashmi H; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS, USA. hamzahashmi87@hotmail.com.; Division of Hematology/Oncology, Medical University of South Carolina, Charleston, SC, USA. hamzahashmi87@hotmail.com.; Memorial Sloan Kettering Cancer Center, New York, NY, USA. hamzahashmi87@hotmail.com.
Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE
Academic Journal
Atallah R; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, Kansas. Electronic address: rawanatallah6@gmail.com.; Ahmed N; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, Kansas.; Ayoobkhan F; Department of Internal Medicine, Trinity Health Oakland/ Wayne State University, Pontiac, Michigan; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, Kansas.; Saif MSI; Department of Biostatistics and Data Science, University of Kansas Medical Center, Kansas City, Kansas.; Logan E; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, Kansas.; Shrestha A; Section of Hematology and Oncology, University of Missouri, Kansas City, Missouri.; Anwer F; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, Kansas.; Mahmoudjafari Z; Department of Pharmacy, University of Kansas Cancer Center, Kansas City, Kansas; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, Kansas.; Mushtaq MU; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, Kansas.; Hashmi H; Department of Medicine, Multiple Myeloma service, Memorial Sloan Kettering Cancer Center, New York City, New York; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, Kansas.; Ganguly S; Houston Methodist Hospital, Houston, Texas.; McGuirk J; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas.; Shebli A; Department of Hematologic Oncology & Blood Disorders, Atrium Health Levine Cancer Institute, Charlotte, North Carolina; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, Kansas.; Abdallah AO; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, Kansas.; Banerjee R; Fred Hutchinson Cancer Center, Seattle, Washington.; Alkharabsheh O; University of South Alabama, Mitchell Cancer Institute, Mobile, Alabama; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, Kansas.
Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101774629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-6367 (Electronic) Linking ISSN: 26666367 NLM ISO Abbreviation: Transplant Cell Ther Subsets: MEDLINE
Managing Infection Complications in the Setting of Chimeric Antigen Receptor T cell (CAR-T) Therapy.
Academic Journal
Ahmed N; Hematologic Malignancies and Cellular Therapeutics University of Kansas Cancer Center.; Oluwole O; Medicine, Hematology and Oncology Vanderbilt University Medical Center.; Mahmoudjafari Z; Hematologic Malignancies and Cellular Therapeutics University of Kansas Cancer Center.; Suleman N; Hematologic Malignancies and Cellular Therapeutics University of Kansas Cancer Center.; McGuirk JP; Hematologic Malignancies and Cellular Therapeutics University of Kansas Cancer Center.
Publisher: International Academy for Clinical Hematology Country of Publication: England NLM ID: 101759455 Publication Model: eCollection Cited Medium: Internet ISSN: 2590-0048 (Electronic) Linking ISSN: 25900048 NLM ISO Abbreviation: Clin Hematol Int Subsets: PubMed not MEDLINE
Academic Journal
Gatwood K; Pharmacy Vanderbilt University Medical Center.; Mahmoudjafari Z; Pharmacy The University of Kansas Cancer Center.; Baer B; Vanderbilt University Medical Center.; Pak S; Pharmacy City Of Hope National Medical Center.; Lee B; City of Hope.; Kim H; City Of Hope National Medical Center.; Abernathy K; Pharmacy Sarah Cannon Research Institute.; Dholaria B; Medicine Hematology Oncology Vanderbilt University Medical Center.; Oluwole O; MedicineHematology and oncology Vanderbilt University Medical Center.
Publisher: International Academy for Clinical Hematology Country of Publication: England NLM ID: 101759455 Publication Model: eCollection Cited Medium: Internet ISSN: 2590-0048 (Electronic) Linking ISSN: 25900048 NLM ISO Abbreviation: Clin Hematol Int Subsets: PubMed not MEDLINE
Academic Journal
Khouderchah CJ; Department of Pharmacy Services and Clinical Pharmacy, Michigan Medicine, Ann Arbor, MI, USA.; Ochs M; University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.; Pianko M; Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.; Mahmoudjafari Z; Department of Pharmacy, University of Kansas Cancer Center, Kansas City, KS, USA.; Snyder J; Department of Pharmacy, University of Kansas Cancer Center, Kansas City, KS, USA.; Ahmed I; University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.; Campagnaro E; Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.; Nachar VR; University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.
Publisher: SAGE Publications Country of Publication: England NLM ID: 9511372 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-092X (Electronic) Linking ISSN: 10781552 NLM ISO Abbreviation: J Oncol Pharm Pract Subsets: MEDLINE
Academic Journal
Dima, D.; Khouri, J.; Raza, S.; Valent, J.; Anwer, F.; Davis, J.A.; Ahmed, N.; Shaikh, H.; Shune, L.; Afrough, A.; Strouse, C.; Mahmoudjafari, Z.; Abdallah, A.-O.; Hashmi, H.; Jia, X.; Sannareddy, A.; Kaur, G.; Anderson, L.D.; Lochner, J.
In: Transplantation and Cellular Therapy . (Transplantation and Cellular Therapy, March 2024, 30(3):308.e1-308.e13)
Academic Journal
Beechinor RJ; UC Davis Comprehensive Cancer Center, Sacramento, CA, USA; UCSF School of Pharmacy, San Francisco, CA, USA. Electronic address: rbeechinor@ucdavis.edu.; Mohyuddin GR; Division of Hematology and Hematological Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.; Mitchell DE; Cancer Patient, President and Founder, Patient for Affordable Drugs, 1120 20th Street NW, Washington, D.C., USA.; Aaron D; S.J. Quinney College of Law, University of Utah, Salt Lake City, USA.; Mahmoudjafari Z; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS, USA; University of Kansas Medical Center, Westwood, KS, USA.
Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101639933 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2213-5383 (Electronic) Linking ISSN: 22135383 NLM ISO Abbreviation: J Cancer Policy Subsets: MEDLINE
검색 결과 제한하기
제한된 항목
[검색어] Mahmoudjafari, Z.
발행연도 제한
-
학술DB(Database Provider)
저널명(출판물, Title)
출판사(Publisher)
자료유형(Source Type)
주제어
언어